Compare Adaptive Biotechnologies Corp (ADPT) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bitdeer Technologies Group — how do they compare? Adaptive Biotechnologies Corp trades at $25.15 (market cap $4.04B), while Bitdeer Technologies Group trades at $9.05 (market cap $2.36B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| ADPT | BTDR | |
|---|---|---|
Market Cap | $4.04B | $2.36B |
Sector | Health | Technology |
52-Week High | $25.45 | $25.90 |
52-Week Low | $12.30 | $7.28 |
Enterprise Value | $4.10B | $3.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
BTDR trades at $9.30, up 6.96% today, but faces bearish technical signals with 13 of 13 moving averages signaling sell. The company reported four consecutive quarterly earnings misses, with Q2 2026 loss of $0.37 per share missing expectations. Despite negative profitability metrics (-28.14% net margin), analyst consensus remains strongly bullish with 82% buy ratings and $22.43 price target. Recent $4.7 billion AI data center deal provides long-term revenue visibility amid Bitcoin mining challenges.
The stock presents high-risk opportunity with significant analyst upside potential but faces execution risks in transitioning from Bitcoin dependency to AI infrastructure. Near-term pressure from negative cash flow and margin compression contrasts with long-term AI contract value. Investors must weigh strong institutional support against persistent profitability challenges and crypto market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
